Lemtrada® (alemtuzumab)

(Intravenous)

Last Review Date: January 1, 2019
Number: MG.MM.PH.90

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Lemtrada® is a recombinant monoclonal antibody that binds to CD52 and causes antibody-dependent cellular cytolysis, complement-mediated lysis, and depletes circulating T and B lymphocytes.

Length of Authorization

Coverage will be approved for 8 doses only; to be administered within a 2 year period and may not be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:

- 96 billable units total (12 billable units per dose)
  - To be administered within a 2 year period (1 dose daily x 5 days followed by 1 dose daily x 3 days, one year later)

Guideline

I. INITIAL APPROVAL CRITERIA

Coverage is provided in the following conditions:

- Patient is 18 years or older; **AND**
- Patient has received a baseline skin exam for melanoma; **AND**
- Patient must not have human immunodeficiency virus infection; AND
- Patient should be screened for the presence of tuberculosis according to local guidelines; AND
- Patient will not receive live vaccines following a course of Lemtrada; AND

Multiple Sclerosis †

- Patient has been diagnosed* with a relapsing form of multiple sclerosis [i.e. relapsing-remitting disease (RRMS) or secondary progressive MS (SPMS) with relapses]; AND
- Confirmed diagnosis* of MS as documented by laboratory report (i.e., MRI); AND
- Prescriber and patient must be enrolled in and meet the conditions of the LEMTRADA REMS program; AND
- Must be used as single agent therapy; AND
- Patient should have had an inadequate response to an adequate trial of two or more drugs indicated for the treatment of MS

† FDA Approved Indication(s)

*Definitive diagnosis of MS with a relapsing-remitting course is based upon BOTH dissemination in time and space. Unless contraindicated, MRI should be obtained (even if criteria are met).

<table>
<thead>
<tr>
<th>Dissemination in time</th>
<th>Dissemination in space</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Development/appearance of new CNS lesions over time)</td>
<td>(Development of lesions in distinct anatomical locations within the CNS; multifocal)</td>
</tr>
<tr>
<td>- ≥ 2 clinical attacks; OR</td>
<td>- ≥ 2 lesions; OR</td>
</tr>
<tr>
<td>- 1 clinical attack AND one of the following:</td>
<td>- 1 lesion AND one of the following:</td>
</tr>
<tr>
<td>o MRI indicating simultaneous presence of gadolinium-enhancing and non-enhancing lesions at any time or by a new T2-hyperintense or gadolinium-enhancing lesion on follow-up MRI compared to baseline scan</td>
<td>o Clear-cut historical evidence of a previous attack involving a lesion in a distinct anatomical location</td>
</tr>
<tr>
<td>o CSF-specific oligoclonal bands</td>
<td>o MRI indicating ≥ 1 T2-hyperintense lesions characteristic of MS in ≥ 2 of 4 areas of the CNS (periventricular, cortical or juxtacortical, infratentorial, or spinal cord)</td>
</tr>
</tbody>
</table>

II. RENEWAL CRITERIA

Coverage cannot be renewed

Dosing/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Indications</td>
<td>Administered by intravenous infusion over 4 hours for 2 treatment courses:</td>
</tr>
<tr>
<td></td>
<td>• First course: 12 mg/day on 5 consecutive days (60 mg total dose)</td>
</tr>
<tr>
<td></td>
<td>• Second course: 12 mg/day on 3 consecutive days (36 mg total dose), 12 months after first treatment course.</td>
</tr>
</tbody>
</table>
Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0202</td>
<td>Injection, alemtuzumab, 1 mg; 1 mg = 1 billable unit</td>
</tr>
</tbody>
</table>

Applicable NDC’s

<table>
<thead>
<tr>
<th>NDC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>58468-0200-xx</td>
<td>Lemtrada 12 mg/1.2 mL single-use vial</td>
</tr>
</tbody>
</table>

ICD-10

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G35</td>
<td>Multiple Sclerosis</td>
</tr>
</tbody>
</table>

Revision History

N/A

References


